Eden Research Share Discussion Threads

[chrischas] 11/6/2019 10:07

Brucie look at the audited accounts.2 full time employees taking a lot of money .
Protecting their nest egg.The company has not developed a lab.Not promoted itself.
Kept the lid on everything . Has gone very quiet since the AGM.The average man,the average buyer of chemicals has never heard of Eden. Year after year the same message .
Just keep the lid on everything and have nice ,quiet profitable life.

[chrischas] 11/6/2019 09:46

Investing: That is a very good summation.

[investingisatrickygame] 11/6/2019 09:36

Chrischas,

Post 6406

You make a good and valid point. I assume that Eden is paying Powerscourt, our mighty PR firm, around £3,000 per month, maybe a bit less. What do we have for that? Well, companies who are more aware of Eden now, but who clearly do nothing and make no investment. So what do we have for our monthly and cumulative fees paid to-date? Absolutely nothing.

Eden continues to invest in the wrong path for the share price, the investment community and for shareholders. Particularly at this moment in time and the evidence is clearly there over the last 3 years.

The two principle directors are taking relatively speaking, significant sums out of the Eden income pot made up of salaries and bonuses. Why take so much when you could make better use some of that pie to drive value in your share price, churn and re-vitalise your share register, elevate your market cap, get interest as a result of the same from the press, then get entry into the papers, make the PR firms job easier and no doubt then make it easier for your broker to sell the stock when it has a higher value and more acceptable entry point.

So you are quote right in my opinion. Some of that money would be better spent promoting the company properly and laying down foundations and a base which we still do not have for the uninitiated. Modern day communication and share price drivers for small cap is not what it used to be and Eden doesn't utilise these channels properly.


I could be wrong, but then the trend of the share price vis-à-vis PR company contribution and performance doesn't lie.

Walbrook PR contributed nothing.

Powerscourt contributes no visible and material value.

And as a broker, Shore Capital contributes diddly squat, so what chance a new broker delivers for you and me.

Eden has so much to offer, yet to me , under delivers materially.

Woolybanana

Hopefully that scenario is not too far away and let's hope that does occur.

[brucie5] 11/6/2019 08:56

Chrischas, could you elucidate what those figures actually mean, before I respond to them? I don't mean your general point, but the figures themselves. Thank you. I understand your underlying message.

[woolybanana] 11/6/2019 08:53

Why has this company not been takenover by one of the big boys yet?

[chrischas] 11/6/2019 08:25

Well they are THE only 2 benefitting out of the company.Thats a lot of money ,part of which could have been used to actually promote the company.

The short ,mid and long term is going straight into their pockets.

[investingisatrickygame] 11/6/2019 00:35

Chriscas,

Your post, 6403. I assume that is irony, right?

For a tech driven company Eden's ascendency is poorly understood and severely undervalued as measured by the share price. Some might argue that sales are slow as your numbers allow for milestone payments included.

[investingisatrickygame] 11/6/2019 00:33

From Super's post, number 6400

hxxps://www.crophealthnorth.co.uk/wp-content/uploads/2019/03/EdwardsGwynn-CropTec-widescreen.pdf

The global market for biopesticides in 2019 is $6 billion

From Eden's 2018 AGM presentation

"Globally, Eden is one of a few biocontrol companies with proven products and regulatory authorisation"

Eden's market Cap is circa £22 million

So which of the other 'few' global players has all the value & the sales?

And what are their market caps?

And how do they differ from Eden?

It appears increasingly strange to me that Eden makes such statements and yet the divide between the statement and Eden's value is like a chasm.


These things need better consideration and deeper explanation if people are to buy the Eden share price. In theory, based on Eden's statement and the 2019 market value then Eden should be priced at £'s, not pence.

'Professional' investors in the City have investment rules, will look for the onset of deep profits, dividends & more. Eden has thus far been unable to penetrate this market and Powerscourt have been unsuccessful in inducing that investment into Eden.

Private investors don't have those rules, they look to get in early and cheap and they look for high capital growth and which point the 'professionals' step in and invest and the Pi's retreat, happy with their ROI.

Eden still needs to address the latter and convince them to buy, something they continually demonstrate a lack of will to do

[chrischas] 10/6/2019 19:48

Eden Research a very profitable business : so sustainable ,so long term.

2012- 90k. 0k
2013- 95k. 0k
2014- 105k. 36k
2015- 122k. 317.5k
2016. 249k. 266.7k
2017. 216k. 258k
2018. 278k. 353k
1061000k. 123000k

mid term and long term that is a great performance!Long may it continue!

[supersonico] 10/6/2019 11:40

One of the Authors Dr Roma Gwynn runs Rational Biopesticide Services.



Despite the chlorotic share price we can only hope that the potential of the Trials and commercial connections Eden are building will lead to future opportunities.





Dr Roma Gwynn has an MSc in Technology for Crop Protection and a PhD in Insect Pathology from Reading University. She is a biopesticide specialist working in technology for 30 years, initially as an insect pathologist research scientist to working for commercial companies in biocontrol product development. She is now an independent specialist. Roma has taken a lead role in the EU and internationally in the development and registration of new biopesticide technologies including semi-chemical, botanical and microbial substances. Her expertise is in facilitating the process of getting biopesticide products onto the market, with particular expertise in efficacy.

Roma is the editor of the ‘The Manual of Biocontrol Agents’ published by BCPC, Chair of the Endowment Committee for the Society of Invertebrate Pathology and a Biopesticide Consultant. Roma has participated in entomopathogenic nematode COST Actions 819 and 850 and is an active member of the International Biocontrol Manufacturers Association.

Roma has been an expert for: the REBECA project for regulation of biocontrol agents, the OECD Biopesticide Steering Group and EU Commission. Roma has also been involved in the development of biopesticide regulatory guidance and is consultant on several biopesticide collaborative research, AGRI-TECH and PhD projects.
…………….

[investingisatrickygame] 10/6/2019 11:10

Super,

A global biopesticide market right now worth $6 billion.

We cannot get away from the facts and the focus must be Eden's share price and who is responsible for it.

Eden has two global bio-active products sold by primary players in the agro-chemical market and has unique technology in Sustaine which is both currently used as a deliverable and also yet to be fully exploited with third parties for single use of their products or/and blending with Eden's active ingredients.

COMPANY STATEMENTS

The only bio-active/pesticide company listed in London.

One of only a few biocontrol companies globally with proven products and regulatory approval.

The last statement is bold and as such and if true, Eden's share price and market capitalisation is a disgrace relative to the current market size.


I see nothing wrong in coming to this conclusion or banging on about it. Eden's share price has flatlined for 3 years. It is in a coma in real terms and being maintained on life support (loyal shareholders who are so far in the red they daren't sell).

People are way too focused on the big blue sky opportunity whilst taking their eye off of value today. Rose tinted glasses does not put money in anyone's pocket today and this is so very typical of AIM stocks.

Eden and their advisers should do much better.

[supersonico] 10/6/2019 10:31

Eden new tweeter friends Newcastle University who's partners include Bayer..

Newcastle University Dr Roma Gwynn Biopesticide Strategist Rationale. The end of industrial agrochemical spraying ? Environmental & health concerns The precautionary principle Decline in new MoA discovery (commercial) Resistance. Global market Increased Over 300% * 2008-2018 BIOPESTICIDES Global market 2019 value over $6 billion* Increase A shift to Biological agents - …

[supersonico] 08/6/2019 23:39

Tenuous is not the word I would use nor Rumour ..just an observation based Guess, like my parallel delay Guess .. but 'most dismal stock in my portfolio' certainly sums the share price up atm.

[dplewis1] 08/6/2019 19:17

Haha, well Eden clearly wins the 'most dismal stock in my portfolio' award so I suppose any form of rumour is interesting, however tenuous!

[supersonico] 08/6/2019 18:38

Not just Someone.. The Right one.

All Guesses all the Time

[dplewis1] 08/6/2019 17:35

Are you suggesting someone is subtly building a stake?

[dplewis1] 08/6/2019 17:22

Have you got a translation for that last post because I've got no idea what any of that means..

[supersonico] 08/6/2019 15:14

Keeping it quiet at Dampenville aka Scandi Noir Nominees tell no tales.

As at 31 May 2019 a nice round 7% what are the chances of that?

The Bank of New York (Nominees) Limited
7,066,500
3.41%

Chase Nominees Limited ALPHAAIF
7,445,000
3.59%



21/10/19

The Bank of New York (Nominees) Limited
7,117,500
3.44%

Chase Nominees Limited ALPHAAIF
6,850,000
3.31%

[investingisatrickygame] 06/6/2019 21:46

It's a pointless tweet. We've been told this several times!

So what; what does it mean for Eden? Explain that properly and you might not have a rotten, underperforming share price.

[dplewis1] 06/6/2019 19:54

Unfortunate the share price is as rotten as that strawberry

[supersonico] 06/6/2019 19:44

Eden Research plc@edenresearch

Botrytis cinerea affects over 200 plant species and causes global crop losses worth up to $100billion each year.
#botrytis #Mevalone #3logy #ARAW #viticulture

[chrischas] 05/6/2019 09:31

Brucie: Great spot.When you plug in the various chem code numbers you see how widespread is the commercial development worldwide.
But I won’t make any further comment.

[supersonico] 05/6/2019 07:16

Not Organic yet but I expect the EGTOP report to be ratified then the three Eden ingredients will be permitted for use in Organic farming systems. That's how I understand it.

[brucie5] 04/6/2019 22:49

Well I think I see. Bugband is cited as an analogous treatment using geraniol. Interesting nevertheless.